62,228 Shares in Agios Pharmaceuticals, Inc. $AGIO Bought by Deutsche Bank AG

Deutsche Bank AG acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the second quarter, HoldingsChannel reports. The institutional investor acquired 62,228 shares of the biopharmaceutical company’s stock, valued at approximately $2,309,000.

Several other institutional investors have also recently added to or reduced their stakes in AGIO. AQR Capital Management LLC lifted its position in shares of Agios Pharmaceuticals by 66.8% in the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock worth $1,498,000 after buying an additional 20,625 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Agios Pharmaceuticals by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock worth $1,274,000 after acquiring an additional 2,920 shares during the period. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals during the first quarter worth about $40,000. Goldman Sachs Group Inc. raised its position in shares of Agios Pharmaceuticals by 16.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock worth $19,299,000 after purchasing an additional 91,482 shares during the period. Finally, Woodline Partners LP acquired a new stake in Agios Pharmaceuticals in the first quarter worth $597,000.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $34.28 on Friday. The business’s 50-day moving average is $35.91 and its 200-day moving average is $31.62. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -4.89 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The company had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider owned 54,645 shares of the company’s stock, valued at $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AGIO. Truist Financial cut their price target on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Friday, July 31st. HC Wainwright upped their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Bank of America raised their price objective on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.25.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.